Smith B W,？ Adams L A. Non-alcoholic fatty liver disease[J]. Crit Rev Clin Lab Sci,？ 2011, 48(3):？ 97-113. [2]Fan J G,？ Farrell G C. Epidemiology of non-alcoholic fatty liver disease in China[J]. J Hepatol,？ 2009, 50(1): 204-210. [3]Williams C D,？ Stengel J,？ Asike M I, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy:？ a prospective study[J]. Gastroenterology, 2011,？ 140(1): 124-131. [4]Tome-Carneiro J,？ Larrosa M,？ Gonzalez-Sarrias A,？ et al. Resveratrol and clinical trials:？ the crossroad from in vitro studies to human evidence[J]. Curr Pharm Des, 2013,？ 19(34): 6064-6093. [5]Chen M L,？ Yi L,？ Jin X,？ et al. Resveratrol attenuates vascular endothelial inflammation by inducing autophagy through the cAMP signaling pathway[J]. Autophagy,？ 2013,？ 9(12): 2033-2045. [6]Li L,？ Hai J,？ Li Z,？ et al. Resveratrol modulates autophagy and NF-kappaB activity in a murine model for treating non-alcoholic fatty liver disease[J]. Food Chem Toxicol,？ 2014,？ 63: 166-173. [7]Xin P,？ Han H,？ Gao D,？ et al. Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type Ⅰ gene expressions in rats[J]. Food Chem Toxicol,？ 2013,？ 52: 12-18. [8]Shang J,？ Chen L L,？ Xiao F X,？ et al. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase[J]. Acta Pharmacol Sin,？ 2008,？ 29(6): 698-706. [9]Poulsen M M,？ Larsen J O,？ Hamilton-Dutoit S,？ et al. Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet[J]. Nutr Res,？ 2012,？ 32(9): 701-708. [10]Brunt E M,？ Kleiner D E,？ Wilson L A,？ et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD:？ distinct clinicopathologic meanings[J]. Hepatology, 2011,？ 53(3): 810-820. [11]Kleiner D E,？ Brunt E M,？ Van-Natta M,？ et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease[J]. Hepatology,？ 2005,？ 41(6): 1313-1321. [12]Salmon D M,？ Flatt J P. Effect of dietary fat content on the incidence of obesity among ad libitum fed mice[J]. Int J Obes,？ 1985,？ 9(6): 443-449. [13]Chen C Y,？ Yi L,？ Jin X,？ et al. Inhibitory effect of delphinidin on monocyte-endothelial cell adhesion induced by oxidized low-density lipoprotein ？via？ ROS/p38MAPK/NF-kappaB pathway[J]. Cell Biochem Biophys,？ 2011,？ 61(2): 337-348. [14]Angulo P. Nonalcoholic fatty liver disease[J]. N Engl J Med,？ 2002,？ 346(16): 1221-1231. [15]Gomez-Zorita S,？ Fernandez-Quintela A,？ Macarulla M T,？ et al. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress[J]. Br J Nutr,？ 2012,？ 107(2): 202-210. [16]Wang G L,？ Fu Y C,？ Xu W C,？ et al. Resveratrol inhibits the expression of SREBP1 in cell model of steatosis ？via？ Sirt1-FOXO1 signaling pathway[J]. Biochem Biophys Res Commun,？ 2009,？ 380(3): 644-649. [17]Quan H Y,？ Kim-do Y,？ Kim S J, et al. Betulinic acid alleviates non-alcoholic fatty liver by inhibiting SREBP1 activity ？via？ the AMPK-mTOR-SREBP signaling pathway[J]. Biochem Pharmacol,？ 2013,？ 85(9): 1330-1340. [18]Xiao X,？ Song B L. SREBP:？ a novel therapeutic target[J]. Acta Biochim Biophys Sin (Shanghai), 2013,？ 45(1): 2-10. [19]Seo M S,？ Hong S W,？ Yeon S H, et al. Magnolia officinalis attenuates free fatty acid-induced lipogenesis ？via？ AMPK phosphorylation in hepatocytes[J].J Ethnopharmacol,？ 2014,？ 157: 140-148. [20]Zhu W,？ Chen S,？ Li Z, et al.Effects and mechanisms of resveratrol on the amelioration of oxidative stress and hepatic steatosis in KKAy mice[J]. Nutr Metab, 2014, 11: 35.
[2]
杨朝霞,代东伶,沈薇.虫草菌丝和还原型谷胱甘肽对非酒精性脂肪肝大鼠模型治疗效果的研究[J].第三军医大学学报,2007,29(22):2176. YANG Zhao-xia,DAI Dong-ling,SHEN Wei.Effect of cordyceps sinensis and reduced glutathione on experimental mouse model with non-alcoholic fatty liver disease[J].J Third Mil Med Univ,2007,29(17):2176. [2]史洪涛,李陶,陈东风.肝细胞色素氧化酶Ⅰ在非酒精性脂肪肝大鼠形成中的作用[J].第三军医大学学报,2006,28(02):160. [3]房殿亮,宁波,沈薇,等.干扰SREBP-1c对内质网应激状态下L02和HepG2肝细胞脂质沉积的影响[J].第三军医大学学报,2013,35(06):513. Fang Dianliang,Ning Bo,Shen Wei,et al.SREBP-1c gene interference decreases lipid accumulation in L02 and HepG2 hepatocytes under endoplasmic reticulum stress[J].J Third Mil Med Univ,2013,35(17):513. [4]王万东,陈东风.非酒精性脂肪变性肝细胞模型中ATF4基因的表达及其意义[J].第三军医大学学报,2010,32(14):1487. Wang Wandong,Chen Dongfeng.Expression and significance of activating transcription factor 4 in oleic acid-induced hepatocyte steatosis in vitro[J].J Third Mil Med Univ,2010,32(17):1487. [5]周婷婷,秦波,郑天鹏,等.非酒精性脂肪肝患者血浆FGF21水平及与肥胖、胰岛素抵抗关系研究[J].第三军医大学学报,2010,32(03):265. Zhou Tingting,Qin Bo,Zheng Tianpeng,et al.Correlation between plasma fibroblast growth factor 21 level, obesity and insulin resistance in nonalcoholic fatty liver disease patients[J].J Third Mil Med Univ,2010,32(17):265. [6]曾志华,曾明慧,冯雯琪,等.电针阻断胰岛素抵抗及过氧化反应治疗非酒精性脂肪肝的实验研究[J].第三军医大学学报,2008,30(11):1055. ZENG Zhi-hua,ZENG Ming-hui,FENG Wen-qi,et al.Electroacupuncture treats rat non-alcoholic fatty liver by blocking insulin resistance and peroxidation[J].J Third Mil Med Univ,2008,30(17):1055. [7]邱烈旺,顾陆昀,吕琳,等.水甘油通道蛋白在非酒精性脂肪变性肝细胞模型中的表达及意义[J].第三军医大学学报,2012,34(07):622. Qiu Liewang,Gu Luyun,Lu Lin,et al.Expression of aquaglyceroporins in nonalcoholic hepatocyte steatosis and its significance[J].J Third Mil Med Univ,2012,34(17):622. [8]肖凯,朱晟易,童钰铃,等.普洱茶水提取物对大鼠非酒精性脂肪性肝病的干预作用[J].第三军医大学学报,2013,35(18):1992. [9]代雪枫,陈东风.非酒精性脂肪肝再生信号转导异常的研究进展[J].第三军医大学学报,2005,27(22):2295. [10]代雪枫,陈东风.大鼠非酒精性脂肪肝形成过程中肝细胞增殖的变化[J].第三军医大学学报,2005,27(09):871.
